

NovoRapid® is a prescription medicine that is fully funded. Before prescribing please review
NovoRapid® Data Sheet available from www.medsafe.govt.nz.

NovoRapid® (insulin aspart (rys)). NovoRapid® contains 100 units/mL insulin aspart (rys) solution for injection. **Indication:** Treatment of diabetes mellitus. **Contraindications:** Hypoglycaemia. Hypersensitivity to insulin aspart or excipients. **Precautions:** Inadequate dosing or discontinuation of treatment may lead to hyperglycaemia and diabetic ketoacidosis. Where blood glucose is greatly improved, e.g. by intensified insulin therapy, patients may experience a change in usual warning symptoms of hypoglycaemia, and should be advised accordingly. The impact of the rapid onset of action should be considered in patients where a delayed absorption of food might be expected. When thiazolidinediones (TZDs) are used in combination with insulin, patients should be observed for signs and symptoms of congestive heart failure, weight gain and oedema; discontinuation of TZDs may be required. **Pregnancy Category:** A. Insulin aspart can be used in pregnancy (see 'Clinical Trials' in full Data Sheet). **Children:** NovoRapid® can be used in children. Clinical experience is available in children aged 2 years and over (see 'Clinical Trials' in full Data Sheet). **Elderly:** No safety issues were raised in elderly patients with type 2 diabetes (mean age 70 years) in a PK/PD trial but careful glucose monitoring may be necessary in elderly patients (see 'Clinical Trials' in full Data Sheet). **Interactions:** Oral hypoglycaemic agents, octreotide, lanreotide, monoamine oxidase inhibitors, non-selective beta-adrenergic blocking agents, angiotensin converting enzyme (ACE) inhibitors, salicylates, alcohol, anabolic steroids, alpha-adrenergic blocking agents, quinine, quinidine, sulphonamides, oral contraceptives, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone, diazoxide, asparaginase, nicotinic acid. **Adverse Effects:** Hypoglycaemia. **Dosage and Administration:** Dosage as determined by physician. NovoRapid® should be administered immediately before a meal, or when necessary after the start of a meal. Discard the needle after each injection. NovoRapid® can be used subcutaneously, intravenously or (10mL vial only) via continuous subcutaneous insulin infusion ('CSII'). (October 2012).